BNP Paribas Financial Markets’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$130M Sell
262,258
-153,367
-37% -$68M 0.05% 359
2026
Q1
$186M Sell
415,625
-143,918
-26% -$67.1M 0.09% 226
2025
Q4
$254M Buy
559,543
+305,200
+120% +$132M 0.11% 162
2025
Q3
$99.6M Sell
254,343
-276,845
-52% -$116M 0.05% 370
2025
Q2
$236M Sell
531,188
-57,149
-10% -$26.3M 0.14% 130
2025
Q1
$285M Sell
588,337
-8,218
-1% -$3.83M 0.17% 121
2024
Q4
$240M Buy
596,555
+153,786
+35% +$71.3M 0.13% 135
2024
Q3
$206M Sell
442,769
-86,116
-16% -$41.4M 0.14% 150
2024
Q2
$248M Buy
528,885
+8,848
+2% +$3.84M 0.2% 103
2024
Q1
$217M Buy
520,037
+127,643
+33% +$54M 0.19% 110
2023
Q4
$160M Buy
392,394
+85,924
+28% +$31.7M 0.18% 118
2023
Q3
$107M Sell
306,470
-62,001
-17% -$21.7M 0.14% 155
2023
Q2
$130M Buy
368,471
+89,387
+32% +$30.1M 0.16% 126
2023
Q1
$87.9M Buy
279,084
+30,763
+12% +$9.23M 0.12% 164
2022
Q4
$71.7M Buy
248,321
+60,914
+33% +$18.6M 0.11% 213
2022
Q3
$54.3M Sell
187,407
-110,531
-37% -$31.8M 0.09% 259
2022
Q2
$84M Buy
297,938
+29,469
+11% +$7.89M 0.13% 168
2022
Q1
$70.1M Buy
268,469
+98,344
+58% +$23.3M 0.09% 216
2021
Q4
$37.4M Buy
170,125
+43,429
+34% +$8.44M 0.05% 392
2021
Q3
$23M Sell
126,696
-41,824
-25% -$8.17M 0.03% 547
2021
Q2
$34M Sell
168,520
-171,819
-50% -$35.9M 0.05% 437
2021
Q1
$73.1M Buy
340,339
+154,204
+83% +$33.9M 0.11% 204
2020
Q4
$44M Sell
186,135
-48,941
-21% -$11.2M 0.08% 239
2020
Q3
$64M Buy
235,076
+42,195
+22% +$11.6M 0.09% 217
2020
Q2
$56M Buy
192,881
+75,473
+64% +$20.5M 0.1% 187
2020
Q1
$27.9M Buy
117,408
+27,485
+31% +$6.3M 0.06% 305
2019
Q4
$19.7M Sell
89,923
-16,551
-16% -$3.35M 0.04% 502
2019
Q3
$18M Sell
106,474
-59,893
-36% -$10.6M 0.03% 517
2019
Q2
$30.5M Sell
166,367
-18,903
-10% -$3.3M 0.06% 334
2019
Q1
$34.1M Buy
185,270
+119,017
+180% +$22M 0.07% 289
2018
Q4
$11M Sell
66,253
-86,742
-57% -$15M 0.03% 598
2018
Q3
$29.5M Sell
152,995
-12,669
-8% -$2.26M 0.04% 413
2018
Q2
$28.2M Buy
165,664
+102,359
+162% +$15.9M 0.05% 385
2018
Q1
$10.3M Sell
63,305
-134,703
-68% -$22M 0.02% 686
2017
Q4
$29.7M Buy
198,008
+89,016
+82% +$13.2M 0.05% 336
2017
Q3
$16.6M Sell
108,992
-30,900
-22% -$4.65M 0.04% 407
2017
Q2
$18M Sell
139,892
-87,825
-39% -$10.6M 0.05% 345
2017
Q1
$24.9M Buy
227,717
+118,127
+108% +$10.4M 0.07% 298
2016
Q4
$8.07M Sell
109,590
-1,471
-1% -$120K 0.04% 418
2016
Q3
$9.69M Sell
111,061
-39,801
-26% -$3.76M 0.04% 304
2016
Q2
$13M Buy
150,862
+51,413
+52% +$4.44M 0.06% 239
2016
Q1
$7.91M Sell
99,449
-46,801
-32% -$4.23M 0.03% 430
2015
Q4
$18.4M Buy
146,250
+28,298
+24% +$3.42M 0.04% 319
2015
Q3
$12.3M Sell
117,952
-118,403
-50% -$15.2M 0.03% 372
2015
Q2
$29.2M Buy
236,355
+59,835
+34% +$7.54M 0.08% 141
2015
Q1
$20.8M Sell
176,520
-53,404
-23% -$6.4M 0.06% 211
2014
Q4
$27.3M Sell
229,924
-397,557
-63% -$44.8M 0.1% 179
2014
Q3
$70.5M Sell
627,481
-50,434
-7% -$4.8M 0.06% 155
2014
Q2
$64.2M Buy
677,915
+429,698
+173% +$30.1M 0.06% 138
2014
Q1
$16.8M Sell
248,217
-155,736
-39% -$12.3M 0.01% 321
2013
Q4
$30M Buy
403,953
+8,425
+2% +$587K 0.02% 221
2013
Q3
$30M Buy
395,528
+233,607
+144% +$18.6M 0.02% 257
2013
Q2
$12.9M Buy
+161,921
New +$11.9M 0.01% 295

Other funds holding VRTX

BNP Paribas Financial Markets's VRTX Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Vertex Pharmaceuticals (VRTX) stake by 37% in Q2 2026, selling an estimated $68M and leaving 262,258 shares worth $130M. The position accounts for 0.05% of the portfolio, ranked #359.

BNP Paribas Financial Markets first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $285M in Q1 2025. 1,467 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • BNP Paribas Financial Markets held 262,258 shares of Vertex Pharmaceuticals worth $130M as of Q2 2026.
  • BNP Paribas Financial Markets sold 153,367 Vertex Pharmaceuticals shares in Q2 2026, an estimated $68M.
  • Vertex Pharmaceuticals made up 0.05% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #359 holding.
  • BNP Paribas Financial Markets first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • BNP Paribas Financial Markets's Vertex Pharmaceuticals position peaked at $285M in Q1 2025.
  • 1,467 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.